[{"id":"299058dd-8801-4728-862b-b08c1fdf3994","acronym":"","url":"https://clinicaltrials.gov/study/NCT04627740","created_at":"2021-01-29T07:21:35.908Z","updated_at":"2024-07-02T16:36:38.710Z","phase":"Phase 1/2","brief_title":"Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT04627740","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TC-A101"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-11-13"}]